Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aclaris Therapeutics

1.44
-0.0100-0.69%
Post-market: 1.460.0191+1.33%16:20 EDT
Volume:401.67K
Turnover:585.57K
Market Cap:155.92M
PE:-1.00
High:1.49
Open:1.46
Low:1.44
Close:1.45
Loading ...

Aclaris Therapeutics Q1 EPS $(0.12), Inline, Sales $1.46M Beat $1.28M Estimate

Benzinga
·
08 May

BRIEF-Aclaris Therapeutics Q1 Net Income USD -15.085 Million Vs. IBES Estimate USD -13.3 Million

Reuters
·
08 May

Aclaris Therapeutics: Qtrly Net Loss $0.12 per Share

THOMSON REUTERS
·
08 May

Aclaris Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
02 May

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer

MT Newswires Live
·
30 Apr

Aclaris Therapeutics Appoints Jesse Hall, M.d. as Chief Medical Officer

THOMSON REUTERS
·
29 Apr

Press Release: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Dow Jones
·
29 Apr

Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment

MT Newswires Live
·
22 Apr

Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial

Dow Jones
·
22 Apr

Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody

THOMSON REUTERS
·
22 Apr

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

GlobeNewswire
·
22 Apr

Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.
·
05 Apr

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

TipRanks
·
19 Mar

Aclaris Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Aclaris Therapeutics initiated with an Outperform at Scotiabank

TIPRANKS
·
07 Mar

Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88%

Simply Wall St.
·
06 Mar

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

GlobeNewswire
·
04 Mar

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year

Simply Wall St.
·
04 Mar

Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
04 Mar

BRIEF-Aclaris Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
28 Feb